These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 7582512

  • 1. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice.
    Collins DR, Pertwee RG, Davies SN.
    Br J Pharmacol; 1995 Jul; 115(6):869-70. PubMed ID: 7582512
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
    Terranova JP, Michaud JC, Le Fur G, Soubrié P.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
    [Abstract] [Full Text] [Related]

  • 3. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice.
    Paton GS, Pertwee RG, Davies SN.
    Neuropharmacology; 1998 Sep; 37(9):1123-30. PubMed ID: 9833642
    [Abstract] [Full Text] [Related]

  • 4. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
    Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR.
    Learn Mem; 2007 Sep; 14(1-2):63-74. PubMed ID: 17202425
    [Abstract] [Full Text] [Related]

  • 5. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice.
    Collins DR, Pertwee RG, Davies SN.
    Eur J Pharmacol; 1994 Jul 11; 259(3):R7-8. PubMed ID: 7982446
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of the sleep-inducing lipid oleamide and cannabinoids on the induction of long-term potentiation in the CA1 neurons of the rat hippocampus in vitro.
    Lees G, Dougalis A.
    Brain Res; 2004 Jan 30; 997(1):1-14. PubMed ID: 14715144
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoid receptor activation in CA1 pyramidal cells in adult rat hippocampus.
    Kirby MT, Hampson RE, Deadwyler SA.
    Brain Res; 2000 Apr 28; 863(1-2):120-31. PubMed ID: 10773200
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct 28; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

  • 9. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP, Huffman JW, Lowe J.
    J Pharmacol Exp Ther; 1998 Sep 28; 286(3):1301-8. PubMed ID: 9732392
    [Abstract] [Full Text] [Related]

  • 10. Modulation of ATP-induced LTP by cannabinoid receptors in rat hippocampus.
    Ievglevskyi O, Palygin O, Kondratskaya E, Grebenyuk S, Krishtal O.
    Purinergic Signal; 2012 Dec 28; 8(4):705-13. PubMed ID: 22453905
    [Abstract] [Full Text] [Related]

  • 11. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.
    Hirst RA, Almond SL, Lambert DG.
    Neurosci Lett; 1996 Dec 13; 220(2):101-4. PubMed ID: 8981483
    [Abstract] [Full Text] [Related]

  • 12. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM, Martin BR.
    Eur J Pharmacol; 2000 Jan 03; 387(1):47-53. PubMed ID: 10633159
    [Abstract] [Full Text] [Related]

  • 13. Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons.
    Hampson RE, Simeral JD, Kelly EJ, Deadwyler SA.
    Hippocampus; 2003 Jan 03; 13(5):543-56. PubMed ID: 12921345
    [Abstract] [Full Text] [Related]

  • 14. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers.
    Rodríguez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M.
    Zhongguo Yao Li Xue Bao; 1999 Dec 03; 20(12):1109-14. PubMed ID: 11189201
    [Abstract] [Full Text] [Related]

  • 15. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
    Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G.
    Proc Natl Acad Sci U S A; 1999 Nov 23; 96(24):14136-41. PubMed ID: 10570211
    [Abstract] [Full Text] [Related]

  • 16. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
    Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM.
    Br J Nutr; 2004 Nov 23; 92(5):757-61. PubMed ID: 15533263
    [Abstract] [Full Text] [Related]

  • 17. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
    Chapman V.
    Br J Pharmacol; 1999 Aug 23; 127(8):1765-7. PubMed ID: 10482905
    [Abstract] [Full Text] [Related]

  • 18. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
    Tanda G, Loddo P, Di Chiara G.
    Eur J Pharmacol; 1999 Jul 02; 376(1-2):23-6. PubMed ID: 10440085
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cannabinoid receptors and reward in the rat: a conditioned place preference study.
    Cheer JF, Kendall DA, Marsden CA.
    Psychopharmacology (Berl); 2000 Jul 02; 151(1):25-30. PubMed ID: 10958113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.